From: Antibiotic use for Vibrio infections: important insights from surveillance data
Fatal N (%) | Non-fatal N (%) | Crude OR (95% CI) | Adjusted OR (95% CI) | |
---|---|---|---|---|
Age, mean (SD) | 56.6 (13.5) | 58.0 (17.8) | 0.995 (0.989-1.001) | 0.99 (0.98-0.998) |
Gender | ||||
Female | 72 (15.2) | 135 (12.6) | reference | reference |
Male | 402 (84.8) | 939 (87.4) | 0.80 (0.59-1.09) | 0.70 (0.49-1.000) |
Year of notification | ||||
1990 – 1996 | 103 (21.7) | 194 (18.1) | reference | reference |
1997 – 2010 | 371 (78.3) | 880 (81.9) | 0.79 (0.61-1.04) | 0.99 (0.73-1.34) |
Pre-existing conditions | ||||
0 | 41 (8.6) | 397 (37.0) | reference | reference |
1 | 107 (22.6) | 277 (25.8) | 3.74 (2.53-5.53) | 4.52 (2.92-6.99) |
2 | 194 (40.9) | 227 (21.1) | 8.28 (5.69-12.03) | 10.30 (6.72-15.78) |
3 or more | 132 (27.8) | 173 (16.1) | 7.39 (4.99-10.95) | 9.31 (5.93-14.62) |
Clinical presentation | ||||
Wound | 68 (14.3) | 406 (37.8) | reference | reference |
Gastroenteritis | 20 (4.2) | 49 (4.6) | 2.44 (1.36-4.35) | 1.52 (0.77-3.01) |
Septicaemia | 333 (70.3) | 493 (45.9) | 4.03 (3.01-5.40) | 2.64 (1.92-3.63) |
Other | 53 (11.2) | 126 (11.7) | 2.51 (1.67-3.79) | 1.69 (1.04-2.74) |
Antibiotic treatment | ||||
Quinolone only | 13 (2.7) | 68 (6.3) | reference | reference |
Quinolone and other/s | 106 (22.4) | 335 (31.2) | 1.66 (0.88-3.12) | 1.44 (0.73-2.84) |
Antibiotic/s, not quinolone | 208 (43.9) | 534 (49.7) | 2.04 (1.10-3.77) | 1.84 (0.95-3.56) |
None | 147 (31.0) | 137 (12.8) | 5.61 (2.97-10.62) | 7.89 (3.94-15.80) |